Attempts Towards Oral Diabetes Therapy by Means of Inhibition of Lipolysis With 5-Methylpyrazole-3-Carbonic Acid

Abstract

The administration of 5 × 20 mg of 5-methylpyrazole-3-carbonic acid daily, extending over a period of days, causes a drop in the levels of free fatty acid and blood sugar in elderly diabetics. Initially, the fasting blood sugar values do not change. After a longer period of time, however, a tendency towards a decrease in fasting sugar values can be observed. By improving the assimilation capacity of exogenously supplied carbohydrates, glycosuria is markedly decreased in poorly controlled diabetics under dietary, sulfonylurea or combined sulfonylurea-biguanide therapy. Raised triglyceride values in the blood were reduced. Hunger ketosis was sharply diminished. In insulin-treated diabetics a therapeutic effect was also observed, but to a lesser degree, In newly discovered, untreated juvenile diabetics, lipolysis is impressively inhibited even though this effect is insufficient for therapeutic purposes; thus in these cases, an effect on the glucose metabolism was not seen.

Tissue examinations of the musculature have shown that the inhibition of lipolysis causes a tendency towards glycogen deficiency in the fasting state and towards glycogen storage during carbohydrate ingestion.

Key words

Inhibition of Lipolysis - Diabetes - 5-Methylpyrazole-3-carbonic acid - Reduction of Triglycerides and Fatty Acids in the Blood - Lowering of Hyperglycemia and Glucosuria